Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Vincenzo Secondo"'
Autor:
Vincenzo Secondo, Anselmo Arlandini, Paolo Quilici, Luca Foppiani, Manlio Cabria, Patrizia Del Monte
Publikováno v:
HORMONES. 8:214-218
Thyroid lymphoma is a rare disease which occurs mainly in elderly females. Most patients with thyroid lymphoma have Chronic Lymphocytic Thyroiditis (CLT), suggesting a role of chronic antigen stimulation in the development of the disease. We present
Autor:
Edoardo Rossi, Enrico Balleari, Marino Clavio, Marco Gobbi, Silvana Timitilli, Marco Grosso, Angela Congiu, Mauro Spriano, Vincenzo Secondo, Riccardo Ghio
Publikováno v:
Annals of Hematology. 85:174-180
Haemopoietic growth factors (HGF), i.e. erythropoietin [recombinant human erythropoietin (rHEPO)] or granulocyte colony stimulating factor (G-CSF), alone or in combination, have largely been used to treat anemia in myelodysplastic syndromes (MDS), bu
Autor:
Enrico Balleari, Sara Aquino, Riccardo Varaldo, Mauro Spriano, Ivana Pierri, Letizia Canepa, Marino Clavio, Edoardo Rossi, Angelo Michele Carella, Marco Gobbi, Giulio Fraternali Orcioni, Francesca Olcese, Annunziata Manna, Riccardo Ghio, Vincenzo Secondo, Filippo Ballerini, Omar Racchi
We retrospectively reviewed 139 stage I–II HL patients who were diagnosed and followed up in an Italian northern region (Liguria) from 1995 to 2007, and who received either chemotherapy (CT) alone (mainly doxorubicin, bleomycin, vinblastine, and da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0644eb5878464ed7ce3770c190a60eab
http://hdl.handle.net/11567/225931
http://hdl.handle.net/11567/225931
Autor:
Valerio Zoli, Antonello Pinto, Emilio Iannitto, Luigi Rigacci, Alessandra Tucci, Vincenzo Secondo, Annunziata Manna, Stefano Pileri, Atto Billio, Pierfederico Torchio, Francesco Zaja, Alessandro Levis, Andrea Gallamini, Caterina Patti, Corrado Tarella, Maria Rosaria Specchia
To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::795a7e73171f9df352cb56a9ec577720
http://hdl.handle.net/2318/40062
http://hdl.handle.net/2318/40062
Autor:
Patrizio Mazza, Andrea Gallamini, A. Levis, Annunziata Manna, Vincenzo Secondo, C. Patti, Cristina Campidelli, Atto Billio, S. A. Pileri, E. Iannitto, Pierfederico Torchio, Livio Gargantini, Antonello Pinto, L. Rigacci, Stefano Ascani, Alessandra Tucci, Valerio Zoli, Francesco Zaja
Publikováno v:
Blood. 108:4732-4732
Prognosis for PTCL patients is poor; the 5-year overall survival rate ranges from 25 to 40%. Despite variable CD52 expression in T-cell malignancies, promising results have been demonstrated with alemtuzumab (Campath ®). We report preliminary result